PainReform Ltd. (NASDAQ:PRFX) Sees Significant Growth in Short Interest

PainReform Ltd. (NASDAQ:PRFX) saw a large growth in short interest in June. As of June 30th, there was short interest totaling 127,699 shares, a growth of 122.3% from the June 15th total of 57,440 shares. Currently, 22.4% of the shares of the stock are short sold. Based on an average daily volume of 2,063,956 shares, the short-interest ratio is currently 0.1 days.

PainReform Stock Down 0.8%

Shares of PainReform stock traded down $0.01 on Wednesday, hitting $1.22. 184,717 shares of the company were exchanged, compared to its average volume of 1,655,200. The company has a 50-day moving average price of $1.60 and a 200 day moving average price of $2.53. The stock has a market capitalization of $1.06 million, a price-to-earnings ratio of -0.00 and a beta of 1.05. PainReform has a 1-year low of $1.18 and a 1-year high of $17.95.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.